Climedo is a digital platform for electronic data collection in decentralized clinical trials. The solution of the Munich startup It is intended to enable faster and more cost-effective approval of pharmaceuticals and medical devices. It also offers post-market surveillance functions, which provide long-term data on the efficacy and safety of products already launched on the market.
The basis for data collection with Climedo's EDC (Electronic Data Capture) system is, among other things, so-called "electronic patient-reported outcomes" (ePRO). Study participants maintain an electronic patient diary that, among other things, queries symptoms. This also benefits the fight against the COVID-19 pandemic: Climedo is making its eDiary solution available to almost half of all German health authorities for tracking (suspected) index cases. This enables the authorities to conduct contactless monitoring without the daily telephone inquiries about symptoms of those affected. Instead, those who test positive and those who have been in contact with the virus fill out a digital questionnaire on their personal smartphone or computer, and the health authorities view all data in a real-time dashboard. This allows them to respond quickly to adverse events.
With the new capital, Climedo plans to accelerate its expansion within Europe and further develop its software. The software will be even more patient-centric and enable complete communication between study coordinators, physicians, and patients in the future. More interfaces, for example, to telemedicine and wearables, are also planned.
“Democratization of drug development”
“Clinical trials are extremely time-consuming and costly for companies,”
so Guillem Sagué, Partner at Nauta Capital.
"This must change. Digitization and decentralization of studies can lead to massive cost savings. This also enables small companies to access clinical trials. At the same time, the approval of drugs for rare diseases is often not worthwhile due to cost reasons – Climedo also wants to change this. Digitization has the potential to make processes significantly more efficient and thus contributes to a democratization of drug development."
And co-founder and CEO Sascha Ritz explained:
"We have set ourselves the ambitious goal of becoming the European market leader for patient-centered, electronic data collection by 2024. Nauta Capital is an investor who has recognized the potential of our decentralized platform and the integration of telemedicine into the world of clinical trials. We are pleased that Nauta Capital is now on our long-term side to expand our partner network and implement our mission."
